Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Hexaell Biotech logo — Pioneering the future of stem cell and artificial organ tech...

Hexaell Biotech

Pioneering the future of stem cell and artificial organ technology with breakthrough solutions for liver failure treatment.

Founded 2015 Series A Total: $7.27M Biotechnology, Health Care

General Information

Company Name Hexaell Biotech
Founded Year 2015
Industries Biotechnology, Health Care
Funding Stage Series A
Social

Get notified when Hexaell Biotech moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Hexaell Biotech

Hexaell Biotech is a groundbreaking startup focused on advancing stem cell and artificial organ technology, with a particular emphasis on innovative solutions for liver failure treatment. Leveraging pioneering research from the Chinese Academy of Sciences, which has been prominently featured in prestigious publications like Nature and Cell Stem Cell, the company has established itself as a trailblazer in the field. With the rights to iHep and HiHep technologies, Hexaell Biotechnology has developed bio-artificial liver medical devices designed to emulate liver function and address liver failure diseases. The company's efforts have culminated in the successful completion of pilot clinical studies involving six liver failure patients at leading hepatopathy centers in China. Founded in 2015, Hexaell Biotechnology operates within the Biotechnology and Health Care industries, aiming to drive meaningful advancements in medical technology. Its most recent milestone is a $7.27M Series A investment secured on 25 December 2018, with funding coming from prominent investors including Hyfinity Investments, Sherpa Healthcare Partners, and Breakthrough Capital. This injection of capital is poised to further propel the development and deployment of the company's pioneering solutions, solidifying its position at the forefront of innovation in the medical technology landscape.

Taxonomy: Stem Cell Research, Artificial Organ Technology, Liver Failure Treatment, Biotechnology Start-up, Chinese Academy of Sciences, Pilot Clinical Studies, Bio-Artificial Liver, Disruptive Technologies, Nature Publication, Cell Stem Cell Publication, iHep Technology, HiHep Technology, Liver Function Replication, Hepatopathy Centers

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A •••••• 3
Investor
•••• •••• 		25 Dec 2018

Hexaell Biotech Alternatives & Competitors

Hexaell Biotech vs
Morphocell Technologies
Morphocell Technologies Canada

Transforming the treatment of liver disease

30 employees
Biotechnology
Hexaell Biotech vs
Promethera Biosciences
Promethera Biosciences

Innovative biopharmaceuticals harnessing healthy human liver cells to treat liver diseases with grou...

Series D
11-50 employees
Biotechnology, Health and Wellness
Hexaell Biotech vs
Vital Therapies
Vital Therapies

Pioneering the future of liver therapy with innovative cell-based treatments for acute liver failure...

Private Equity
Biotechnology, Health Care
Also compare with: Hexaell Biotech vs NEXEL NEXEL

FAQ About Hexaell Biotech

Pioneering the future of stem cell and artificial organ technology with breakthrough solutions for liver failure treatment.
Hexaell Biotech was founded in 2015.
Hexaell Biotech operates in the following industries: Biotechnology, Health Care.
Hexaell Biotech has completed 1 funding round, raising a total of $7.27M. The latest funding stage is Series A.
Top alternatives and competitors to Hexaell Biotech include Morphocell Technologies, Promethera Biosciences, Vital Therapies, BioLamina, Parse Biosciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Hexaell Biotech and Morphocell Technologies are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Hexaell Biotech and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy